AgentixAGTX Days Payable is 0.00 as of Mar. 2026. The stock has 3 warning signs investors should review. Among 704 Biotechnology companies, Agentix ranks worse than 142045.31% on this metric.
The historical rank and industry rank for Agentix's Days Payable or its related term are showing as below:
During the past 12 years, Agentix's highest Days Payable was 1095.00. The lowest was 1095.00. And the median was 1095.00.
AGTX's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56 * Ranked among companies with meaningful Days Payable only.
Agentix's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Agentix Days Payable Related Terms
Agentix Days Payable Historical Data
* Premium members only.
The historical data trend for Agentix's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Agentix's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agentix Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agentix's Days Payable distribution charts can be found below:
* The bar in red indicates where Agentix's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Agentix's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agentix (AGTX) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Agentix and its competitors. Over the past decade, Agentix's Days Payable has ranged from 1,095.00 to 1,095.00. According to the industry distribution chart, Agentix ranks #999999 out of 704 companies in the Biotechnology industry.
Is Agentix's Days Payable too high?
Agentix's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 1,095.00 to a high of 1,095.00. Based on the distribution chart, Agentix ranks #999999 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Agentix's Days Payable compare to BZYR and ATXI?
According to the Biotechnology industry distribution chart, Agentix ranks #999999 out of 704 companies for Days Payable. This places Agentix in the lower half of its industry. The industry median Days Payable is 113.56. Historically, Agentix's own Days Payable has ranged from 1,095.00 to 1,095.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Agentix and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agentix's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agentix stock overvalued right now?
Agentix (AGTX) has a current Days Payable of 0.00. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Agentix (AGTX), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGTX has been successfully added to your 